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Chemical synthesis Scheme S1. Synthesis of C2-H analogues. Reagents and conditions: (i) 7-deaza-6-chloro-purine, Ph 3 P, DIAD, THF, rt (ii) 40% MeNH 2 , MeOH; (iii)10% TFA, MeOH, 70 o C.
Ethyl (3aR,3bS,4aS,5R,5aS)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (60)
DIAD (0.22 mL, 1.13 mmol) was added to a solution of triphenylphosphine (0.296 g, 1.13 mmol) and 7-deaza-6-chloro-purine (0.173 g, 1.13 mmol) in dry THF (4 mL) at 0 o C and after addition it was stirred at room temperature for 10 min. A solution of compound 59 (0.137 g, 0.566 mmol) in THF (2 mL) was added to the reaction mixture, and the mixture stirred overnight at room temperature. Solvent was evaporated and the residue was purified on flash silica gel column chromatography (hexane:ethyl acetate = 5:1) to give compound 60 (0.134 g, 63%) as a colorless foamy solid. was evaporated under vacuum and the residue was purified on flash silica gel column chromatography (CH 2 10% TFA (2 mL) was added to a solution of compound 62 (60 mg, 0.168 mmol) in MeOH (2 mL) and heated at 70 o C for 3 h. Solvent was evaporated and the residue was purified on flash silica gel column chromatography (CH 2 Cl 2 :MeOH = 10:1) to give compound 17 (45 mg, 85%) as a colorless syrup.
1 H NMR (CD 3 40% methylamine solution (2.0 mL) was added to a solution of compound 93a (38 mg, 0.065 mmol) in methanol (2 mL) and the mixture stirred at room temperature overnight. Solvent was evaporated under vacuum and the residue was purified on flash silica gel column chromatography (CH 2 n-BuLi (1.32 mL, 1.6M solution in hexane) was added dropwise to a solution of 2,2,6,6-tetramethyl pyridine (0.36 mL, 2.12 mmol) in THF (3 mL) at -78 o C. After 5 min, a solution of compound 36 (160 mg, 0.42 mmol) in THF (1 mL) was added and finally Bu 3 SnCl (0.57 mL, 2.12 mmol) to the reaction mixture and the mixture stirred for 1.5 h under the same conditions. The reaction mixture was quenched with saturated NH 4 Cl solution. Aqueous layer was extracted with ethyl acetate (3 times) and the combined organic layer was washed with brine, dried over Na 2 SO 4 , filtered and evaporated. The residue was roughly purified on flash silica gel column chromatography (hexane:ethyl acetate = 10:1) to give compound 63 (121 mg, 42%) as a syrup. 
1-((3aR,3bS,4aS,5R,5aS)-5-(4-
Chloro
1-((3aR,3bS,4aS,5R,5aS)-5-(2-((5-Chlorothiophen-2-yl)ethynyl)-4-(methylamino)-7H-

1-((1S,2R,3S,4R,5S)-4-(2-((5-Chlorothiophen-2-yl)ethynyl)-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxybicyclo[3.1.0]hexan-1-yl)pentan-1-one (44)
10% TFA (2.5 mL) was added to a solution of compound 66 (13 mg, 0.024 mmol) in MeOH (2.5 mL) and heated at 70 o C for 3 h. Solvent was evaporated and the residue was purified on flash silica gel column chromatography (CH 2 
4-Chloro-2-(tributylstannyl)-7-(triisopropylsilyl)-7H-pyrrolo[2,3-d]pyrimidine (69)
n-BuLi (5.6 mL, 1.6 M solution in hexane) was added dropwise to a solution of 2,2,6,6-tetramethyl pyridine (1.5 mL, 9.0 mmol) in THF (10 mL) at -78 o C. After 5 min, a solution of compound 68 (559 mg, 9.0 mmol) in THF (5 mL) was added, followed by Bu 3 SnCl (2.43 mL, 9.0 mmol) to the reaction mixture and the mixture stirred for 2 h under the same conditions. The reaction mixture was quenched with saturated NH 4 Cl solution. Aqueous layer was extracted with ethyl acetate (3 times) and the combined organic layer was washed with brine, dried over Na 2 SO 4 , filtered and evaporated. The residue was purified on flash silica gel column chromatography (hexane:ethyl acetate = 60:1) to give compound 69 (832 mg, 77%) as a colorless syrup. 
4-Chloro-2-iodo-7-(tri-isopropylsilyl)-7H-pyrrolo[2,3-d]pyrimidine (70)
Iodine (528 mg, 2.08 mmol) was added to a solution of compound 69 (832 mg, 1.38 mmol) in THF (10 mL) and the mixture stirred for 2 h at room temperature. Na 2 S 2 O 3 solution was added to the reaction mixture and aqueous layer was extracted with ethyl acetate (3 times). The combined organic layer was washed with brine, dried (Na 2 SO 4 ), filtered and evaporated. The residue was purified on flash silica gel column chromatography (hexane:ethyl acetate=60:1) to give compound 70 (413 mg, 68%) as a colorless syrup.
1 H NMR (CDCl 3 , 400 MHz) δ 7.21 (d, J = 3.6 Hz, 1H), 7.00 (d, J = 3.6 Hz, 1H), 1.70-1.62 (m, 3H), 1.14 (d, J = 7.6 Hz, 18H). HRMS calculated for C 14 Alternate DAT radioligands used in the laboratory of A. Janowsky: 
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Molecular Modeling Methods
Computational facilities. Ligand geometry optimization, homology modeling and molecular docking simulations were carried out using a 6 Intel® Xeon® E5-1650 v3 CPU workstation. Membrane MD simulations were run on one NVIDIA® 980Ti GTX and one NVIDIA® 1080 GTX.
Ligand Preparation. Selected compounds were built using Maestro 1 and subjected to gas phase geometry optimization with the Jaguar 9.1 quantum chemistry package 2 using density functional theory (DFT) with the B3LYP hybrid functional and the 6-31G** basis set.
Homology modeling. The hKOR homology model was built upon the X-ray structure of the JDTic-hKOR complex. 3 The template structure and the amino acid sequence were retrieved from the RCSB PDB database 4 (http://www.rcsb.org, PDB ID: 4DJH) and the Universal Protein Resource 5 (UniProt IDs: P41445), respectively. The X-ray structure was pre-processed as follows: after manual removal of the lysozime (T4L) fusion protein and solvent atoms, ionization states of protein sidechains and hydrogen positions were assigned with the Protein Preparation Wizard 6 tool by retaining the co-crystallized ligand and water molecules. Prime 4.5 7 was used to build the homology model (ClustalW alignment method and knowledge-based building method) and to reconstruct and refine missing loop domains. N-terminal and C-terminal portions were not modeled if their lengths exceeded those of the template.
Protonation state of His291 (6.52).
After building the hKOR homology model, we carefully assessed the protonation state of His291 (6.52) by examining the H-bond pattern with surrounding residues and water molecules and by comparing the KOR structure with the X-ray structures of other ORs (namely MOR, PDB ID: 4DKL and DOR, PDB ID: 4N6H). In the X-ray structures, His(6.52) establishes a H-bond with the aromatic hydroxyl moiety of the cocrystallized morphinan antagonists through the interplay of two highly conserved water molecules. This H-bond pattern, therefore, requires His291 (6.52) protonated on the N ε atom (hereby denoted as HSE). However, as a preliminary docking analysis of 28 did not predict the presence of a H-bond donor moiety in the proximity of His291 (6.52), we also considered the residue protonated on the N δ (hereby denoted as HSD). We therefore and carried out MD simulations by considering both HSE and HSD protonation states for His291 (6.52) and compared the two sets of results.
Induced Fit Docking (IFD).
Compound 28 was docked to the homology model by means of the IFD 8 procedure based on Glide search algorithm using the Standard Protocol (SP) and OPLS3 force field. 9 The centroid of the co-crystallized JDTic ligand 3 was selected as center of the Glide grid (inner box side = 10 Å; outer box side = auto). The ligand was initially docked rigidly into the receptor by applying a scaling factor of 0.5 to both ligand and protein van der Waals (vdW) radii. Up to 20 poses were collected, and the sidechains of residues within 5 Å of the ligand were refined with Prime. 7 The ligand was re-docked into the newly generated receptor conformations with Glide 8 by generating up to 10 poses using the SP scoring function and reverting the vdW radii scaling factors to their default values.
Molecular dynamics (MD).
The best obtained docking complex of 28 was subjected to 30 ns of membrane MD simulations run in triplicate by considering His291 (6.52) both as HSE and HSD. The ligand-protein systems were embedded in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayer (80x80 Å wide, generated through the VMD 10 Membrane Plugin tool) according to the orientation suggested by the "Orientations of Proteins in Membranes (OPM)" server. 11 Overlapping lipids (within 0.6 Å) were removed upon protein insertion and the systems were solvated with TIP3P 12 water and neutralized by Na + /Cl -counterions (final concentration 0.154 M). MD simulations with periodic boundaries conditions were carried out with ACEMD 13 using CHARMM36 14, 15 force field for lipid and protein atoms, and CGenFF(3.0.1) 16, 17 force field for ligand atoms. Ligand parameters were obtained by analogy through the ParamChem service (https://cgenff.paramchem.org, accessed 08/2017, version 1.0.0) with no further optimization. The force constants of the υ 0 and υ 1 dihedral angles of the (N)-methanocarba ring (coinciding with υ 1 and υ 2 , respectively) was increased to 4.0 kcal/mol to avoid unfeasible south ring puckering. The systems were equilibrated through a stepwise procedure: in the first phase, after 2500 cycles of conjugate-gradient minimization aimed at reducing steric clashes arising from the manual setup of the system, 10 ns of MD simulation were performed in the NPT ensemble, restraining protein (and ligand) atoms by a force constant of 1 kcal/mol·Å 2 . In the second phase, once water molecules diffused inside the protein cavity and the lipid bilayer reached equilibrium, the constraints on the ligand atoms were maintained whereas those on protein atoms were removed except for alpha carbon atoms (force constant = 0.5 kcal/mol·Å 2 ) for other 10 ns. During the equilibration procedure, the temperature was maintained at 310 K using a Langevin thermostat with a low damping constant of 1 ps -1 , and the pressure was maintained at 1 atm using a Berendensen barostat. Bond lengths involving hydrogen atoms were constrained using the M-SHAKE 18 algorithm with an integration timestep of 2 fs. The equilibrated systems were subjected to 30 ns of unrestrained MD simulations (NVT ensemble, damping constant of 0.1 ps -1 ) run in triplicates. Long-range Coulomb interactions were handled using the particle mesh Ewald summation method (PME) 19 with grid size rounded to the approximate integer value of cell wall dimensions. A non-bonded cutoff distance of 9 Å with a switching distance of 7.5 Å was used.
MD Trajectory Analysis.
MD trajectory analysis was performed with an in-house script exploiting the NAMD 2.10 20 mdenergy function and the RMSD trajectory tool (RSMDTT) implemented in VMD 10 . Selection of a representative trajectory was based upon the total ligandprotein interaction energy (IE tot ) expressed as the sum of van der Waals (IE vdW ) and electrostatic (IE ele ) contribution as previously described 21 . For both the HSD and HSE systems the trajectory characterized by low average ligand RMSD value and achieving the ligand-protein complex with the lowest IE value was selected for a more detailed analysis and visualization (see Table S2 ). 22, 24, 30-37 . The ligand-protein complexes characterized by the lowest IE values extracted from the MD trajectories for both the HSE and HSD systems were minimized and prepared for docking calculations by retaining water molecules directly interacting with the ligand or connecting surrounding protein residues with the conserved Asp138 (3.32). Selected compounds were docked to the 28-hKOR MD so-refined structures with Glide 22 by generating up to 5 poses using the SP scoring function. The centroid of 28 was selected as center of the Glide grid (inner box side = 10 Å; outer box side = 30 Å). ) on the KOR X-ray structure (grey ribbons) and the hypothetical binding mode of 28 (cyan carbon atoms, balls and stick representation) at the hKOR HSE model (cyan ribbons) suggested by our MD simulations. Transparent green and red spheres correspond to "happy" and "unhappy" water molecules, respectively. Highlighted water molecules are represented with a higher sphere radius. Green and red circle highlight the proximity or superimposition between hydrophobic substituents and "unhappy" water molecules and hydrophilic substituents with "happy" water molecules, respectively. Water molecules in the proximity of the ligand (radius = 5Å) detected during our MD simulations are represented as cyan spheres. 5 mL of 100 mM Sodium pyruvate, 5 mL of 100X non essential amino acids, 5 mL of Penstrep was added to 100 mL of heat inactivated fetal bovine serum to 385 mL of DMEM aseptically and mixed thoroughly.
Docking of compounds
Molecular Modeling Results
Preparation of Hank's Balanced salt solution (HBSS) pH 7.4:
One vial of Hank's balanced salt (Sigma-H1387) was dissolved in 900 mL of milli Q water; adjusted the pH to 7.4 and made up the volume to 1000 mL with the same. The solution was filter sterilized and store at 4 o C.
Preparation & Dilution of Test Compound:
10 mM stock solution of test compound was prepared in DMSO. 10 mM stock was diluted with HBSS Buffer to a final concentration of 10 µM.
Assay:
Revival 
Pre-Assay Preparation:
On the day of assay, medium was removed and washed twice with HBSS Buffer and incubated with HBSS buffer for 30 min in an incubator and wells with TEER values greater than 230 ohm.cm 2 were selected for the incubation. 4.6 Apical to Basal permeability with 2% BSA: 75 µL of test compound was added to apical wells and 250 µL of HBSS buffer with 2% BSA was added to basal wells. 25 µL of basal samples was collected at 120 min and processed as stated below.
Basal to Apical permeability with 2% BSA:
250 µL of test compound was added to basal wells and 75 µL of HBSS buffer with 2% BSA was added to apical wells. 25 µL of apical samples was collected at 120 min and processed as stated below.
Sample processing:
Single point calibration curve in HBSS buffer with 2% BSA was used. Donor samples were diluted 1:1 with HBSS containing 2% BSA and receiver samples were diluted with 1.1 HBSS buffer and precipitated with 200 µL of acetonitrile containing internal standard and vortexed for 5 min @ 1000 rpm, centrifuged at 4000 rpm for 10 min. 100 µL of supernatant was diluted with 200 µL of water and submitted for LC-MS/MS analysis. 4.9 Calculations: Papp = dQ/dT x 1/Co x 1/A, dQ is amount permeated to the receiver compartment of the 96 well filter plate; dT is Time of incubation of drug on the cell monolayer; Co is initial concentration of drug in the apical compartment of the well; A is surface area of the filter. Sodium hydroxide (pellets, 0.42 g), monobasic potassium phosphate (3.954 g), and sodium chloride (6.186 g) were dissolved in 500 mL of purified water in a 1 L of volumetric container. The pH of the buffer was adjusted to exactly 6.5 using either 1 N sodium hydroxide or 1 N hydrochloride and the volume made up to 1 L with water.
Preparation and Dilution of Test Compound:
10 mM stock solution of test compound was prepared in DMSO and diluted with water: acetonitrile (1:1) to a concentration of 1 mM. Working concentration of 100 µM was prepared by further dilution with water: acetonitrile (1: 1).
Preparation of FaSSGF buffer, pH 1.60: 1.999 g of NaCl was dissolved in 900 mL of milli q water. pH was adjusted to 1.6 with HCl and final volume was made up to 1000 mL with milli q water 0.060 g of SIF powder was added to 1000 mL of NaCl/HCl solution
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Preparation of FaSSIF buffer, pH 6.50: 0.420 g of NaOH, 3.438 g of NaH 2 PO 4 , 6.186 g of NaCl was added to 900 mL of milli q water. pH was adjusted to 6.5 with 1N NaOH/1N HCl. 2.240 g of SIF powder was added to 1000 mL of buffer and allowed to stand at room temperature for 2 h, to opalescence. Protocol:
